SkinBioTherapeutics (UK) Insiders
| SBTX Stock | 15.88 0.12 0.75% |
SkinBioTherapeutics employs about 11 people. The company is managed by 6 executives with a total tenure of roughly 26 years, averaging almost 4.0 years of service per executive, having 1.83 employees per reported executive. Breaking down SkinBioTherapeutics' management performance can provide insight into the firm performance.
| Catherine ONeill Insider Chief Board |
| Manprit Randhawa Insider Chief Officer |
SkinBioTherapeutics |
SkinBioTherapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.6118) % which means that it has lost $0.6118 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.1864) %, meaning that it generated substantial loss on money invested by shareholders. SkinBioTherapeutics' management efficiency ratios could be used to measure how well SkinBioTherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, SkinBioTherapeutics' Total Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 3.1 M in 2024, despite the fact that Non Currrent Assets Other are likely to grow to (746.8 K).Common Stock Shares Outstanding is likely to drop to about 139.6 M in 2024. Net Loss is likely to gain to about (2.2 M) in 2024
SkinBioTherapeutics Workforce Comparison
SkinBioTherapeutics PLC is currently regarded as top stock in number of employees category among its peers. The total workforce of Consumer Staples industry is at this time estimated at about 396. SkinBioTherapeutics holds roughly 11.0 in number of employees claiming about 2.78% of stocks in Consumer Staples industry.
SkinBioTherapeutics PLC Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. SkinBioTherapeutics PLC Price Series Summation is a cross summation of SkinBioTherapeutics price series and its benchmark/peer.
SkinBioTherapeutics Notable Stakeholders
A SkinBioTherapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as SkinBioTherapeutics often face trade-offs trying to please all of them. SkinBioTherapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting SkinBioTherapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Catherine ONeill | Chief Board | Profile | |
| Manprit Randhawa | Chief Officer | Profile | |
| Stuart Ashman | CEO Director | Profile | |
| Melissa Greenwell | Group Controller | Profile | |
| Douglas Quinn | Company Sec | Profile | |
| Laura Bey | Head Formulations | Profile |
About SkinBioTherapeutics Management Performance
The success or failure of an entity such as SkinBioTherapeutics PLC often depends on how effective the management is. SkinBioTherapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of SkinBioTherapeutics management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the SkinBioTherapeutics management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
SkinBioTherapeutics is entity of United Kingdom. It is traded as Stock on LSE exchange.
Please note, the imprecision that can be found in SkinBioTherapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of SkinBioTherapeutics PLC. Check SkinBioTherapeutics' Beneish M Score to see the likelihood of SkinBioTherapeutics' management manipulating its earnings.
SkinBioTherapeutics Workforce Analysis
Traditionally, organizations such as SkinBioTherapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare SkinBioTherapeutics within its industry.SkinBioTherapeutics Manpower Efficiency
Return on SkinBioTherapeutics Manpower
| Revenue Per Employee | 12K | |
| Revenue Per Executive | 22K | |
| Net Loss Per Employee | 257.7K | |
| Net Loss Per Executive | 472.5K | |
| Working Capital Per Employee | 108.3K | |
| Working Capital Per Executive | 198.5K |
Additional Tools for SkinBioTherapeutics Stock Analysis
When running SkinBioTherapeutics' price analysis, check to measure SkinBioTherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SkinBioTherapeutics is operating at the current time. Most of SkinBioTherapeutics' value examination focuses on studying past and present price action to predict the probability of SkinBioTherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SkinBioTherapeutics' price. Additionally, you may evaluate how the addition of SkinBioTherapeutics to your portfolios can decrease your overall portfolio volatility.